BioCentury
ARTICLE | Clinical News

Supinoxin: Ph IIa started

March 3, 2017 5:39 PM UTC

Rexahn began an open-label, U.S. Phase IIa trial to evaluate Supinoxin in up to 50 patients who have failed prior therapies. ...

BCIQ Company Profiles

Rexahn Pharmaceuticals Inc.